Ignite Creation Date:
2024-05-06 @ 3:26 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02287298
Status:
COMPLETED
Last Update Posted:
2016-04-06
First Post:
2014-09-19
Brief Title:
Triple Combination Therapy of Choroidal Neovascularization in AMD a Cost Effect and Efficient Therapeutic Treatment
Sponsor:
The Retina Center of St Louis County PC
Organization:
The Retina Center of St Louis County PC
Study Overview
Official Title:
Triple Combination Therapy of Choroidal Neovascularization in Exudative Age-related Macular Degeneration - a Cost Effect and Efficient Therapeutic Treatment
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy Bevacizumab Dexamethasone and Photo-dynamic therapy during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin
Detailed Description:
Study parameters will include best corrected visual acuity number of combination treatments reduction of central foveal thickness by OCT measurement and development of exudative macular degeneration in the fellow eye Follow up will include all patients with a minimum of two years Retrospective review of patient charts in the office of The Retina Center
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None